NewLink Genetics Gets FDA Approval for Ebola vaccine ERVEBO

published 11:11 pm ET December 27th, 2019

On December 20, NewLink Genetics Corporation (NLNK) announced that after a priority review, the FDA approved ERVEBO®, or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP). This is the first Ebola vaccine approved by the FDA. Merck (MRK) partnered with NewLink Genetics in the development of the vaccine.

 

Jet Equities detected the event and issued an alert at 10:09 am. The last trade took place at $1.70. NewLink’s stock price rose higher following the announcement, and the stock continued to experience gains over the next five trading sessions. NewLink Genetics closed at $2.77 on December 27 for a gain of 63%.

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

Subscribe here if you would like to start receiving these signals in real-time and start trading!